FDA Advisers Overwhelmingly Oppose Approval of MDMA As a Psychotherapeutic Catalyst

The panel's recommendation, based on several concerns about two clinical trials, is a serious setback for a promising PTSD treatment.

Related Keywords

,David Millis ,Melissa Decker Barone ,Rick Doblin ,Alexander Shulgin ,Jerry Rosenbaum ,Amy Emerson ,Department Of Veterans Affairs ,Multidisciplinary Association For Psychedelic Studies ,Drug Administration ,Institute For Clinical ,Drug Enforcement Administration ,Lykos Therapeutics ,Multidisciplinary Association ,Psychedelic Studies ,Veterans Affairs ,Nature Medicine ,Economic Review ,